Redeye leaves its comments on Respiratorius following its Q3 report (split calendar year).
The report itself was undramatic, but we see that the positive results from the PK study are
positive in terms of partner possibilities for VAL001.
ANNONS
Redeye leaves its comments on Respiratorius following its Q3 report (split calendar year).
The report itself was undramatic, but we see that the positive results from the PK study are
positive in terms of partner possibilities for VAL001.